About the Alzheimer’s Drug Discovery Foundation (ADDF)
The Alzheimer’s Drug Discovery Foundation’s (ADDF) sole mission is to rapidly
accelerate the discovery and development of drugs to prevent, treat and cure
AD, related dementias and cognitive aging.
ADDF was established in 2004 to expand upon the programs initiated by the
Institute for the Study of Aging (ISOA) Inc., a private foundation founded by the
Estée Lauder family in 1998. We use a venture philanthropy investment model to
bridge the global funding gap between basic research and later-stage
development, recycling any return on investment to support new research.
ADDF has an impressive track record of selecting and supporting excellent
Alzheimer’s disease (AD) drug discovery research. Our scientists have created
entirely new classes of drugs in development for AD, screened millions of
compounds, identified hundreds of leads, executed tens of patents and
licenses, and have advanced compounds into clinical trials. To date, we have
awarded over $33M for more than 240 research programs and conferences in
12 countries.
8
thInternational Conference on Alzheimer’s Disease Drug Discovery
The Alzheimer’s Drug Discovery Foundation’s (ADDF) organizes an annual
two-day global conference for research scientists to engage in discussion and cross
fertilization of ideas focusing on Alzheimer’s drug discovery research. Designed
specifically for academic and industry scientists, the conference gives
8
TH
INTERNATIONAL CONFERENCE ON
ALZHEIMER’S DISEASE DRUG DISCOVERY
FINAL PROGRAM
MONDAY, OCTOBER 15, 2007
7:45 – 8:30 am Registration & Continental Breakfast
8:30 – 8:40 Welcome & Opening Remarks Howard Fillit, MD, Executive Director, ADDF
8:40 – 9:10 Plenary Talk
Jeffrey S. Nye, MD, PhD, Johnson and Johnson
Pharmaceutical R&D, LLC
I. NEUROPROTECTION
Session Chair Frank Longo, MD, PhD, Stanford University
9:10 – 9:30
The Nrf2 Mediated Pathway as a Therapeutic Target in
Alzheimer's Disease Jari Koistinaho, MD, University of Kuopio
9:30 – 9:50
Novel C-terminal Proteolysis of APP as a Therapeutic Target
for Alzheimer’s Disease Varghese John, PhD,Buck Institute
9:50 – 10:10
Small Molecule p75 NTR and TrkB Ligands for Alzheimer's
Disease Therapeutics Frank Longo, MD, PhD, Stanford University
10:10 – 10:30 Panel Discussion
10:30 – 10:50 Break
10:50 – 11:10
Combinatorial Approaches to Small Molecule NGF Receptor Agonists
Nicholas Webster, PhD, Veterans Medical
Research Foundation
11:10 – 11:30
Why Do We Need Novel Multimodal Neuroprotective and Neurorestorative Drugs for Alzheimer's Disease?
Moussa B.H. Youdim, PhD, Technion -Israel
Institute of Technology
11:30 – 11:50 Bone Marrow-Mobilizing Agents for Alzheimer's Disease
Juan Sanchez-Ramos, MD, PhD,University of
South Florida 11:50 am –
12:10 pm The CKI Pathway in Age-Related Diseases Igor Roninson, PhD, Senex Biotechnology, Inc.
12:10 – 12:30 Panel Discussion
12:30 – 2:00 Lunch
II. ANTI-AMYLOID AND MISFOLDING
Session Chair
Michael Wolfe, PhD,Brigham and Women’s
Hospital and Harvard Medical School
2:00 – 2:20
Hsp90, Degradation and Tau: Clinical implications of Basic
Research Leonard Petrucelli, PhD, Mayo Clinic
2:20 – 2:40 ApoE Amyloid Connection Thomas Wisniewski, MD, New York University
2:40 – 3:00
Anti-amyloidogenic Properties of Resveratrol and its Analogues
Philippe Marambaud, PhD, NSLI Jewish
Research Inst.
3:00 – 3:20
Commercialization of BRI-based Peptides for the Treatment of Alzheimer's Disease
Luciano D'Adamio, MD, PhD,Albert Einstein
College of Medicine
3:20 – 3:40 Panel Discussion
3:40 – 4:00 Break
4:00 – 4:20 Efficacy of Small Molecule Assembly Blockers
William F. Goure, PhD, Acumen
Pharmaceuticals
4:20 – 4:40 Selective Amyloid-lowering Agents
Michael Wolfe, PhD,Brigham and Women’s
Hospital and Harvard Medical School 4:40 – 5:00 Panel Discussion
Final Program (cont.)
TUESDAY, OCTOBER 16, 2007
7:45 – 8:30 am Continental BreakfastIII. MISFOLDING II
8:30 – 8:50
Plant-based Primary Screen and Animal-based Secondary Screens for Chaperone Inducing Drugs Against Protein
Misfolding in Alzheimer's Disease Pierre Goloubinoff, PhD, University of Lausanne
8:50 – 9:10
Development of Hsp90 Inhibitors as Novel Therapeutics for AD
Gabriela Chiosis, PhD, Memorial
Sloan-Kettering Cancer Center
9:10 – 9:30
NADPH Oxidase as a Therapeutic Target in Alzheimer's Disease
Michelle Block, PhD, Virginia Commonwealth
University 9:30 – 9:50 Panel Discussion
9:50 – 10:10 Break
IV. ANTI-TANGLES
Session Chair
Eva-Maria Mandelkow, MD, PhD,
Max-Planck-Unit for Structural Mol. Biology
10:10 – 10:30 Molecular Targets for Tau Pathology
Eva-Maria Mandelkow, PhD, Max Planck Unit
for Structural Biology
10:30 – 10:50
Distal Cis-Elements and Compounds that Regulate Tau Splicing
Jianhua Zhou, PhD, University of Massachusetts
Medical School
10:50 – 11:10
p25/Cdk5, the Missing Link to a Reactivation of the Cell Cycle in Neurofibrillary Degeneration
Luc Buee, PhD, French National Institute for Health and Medical Research
11:10 – 11:30
Tau-focused Drug Discovery for
Alzheimer's Disease and Related Tauopathies
John Trojanowski, MD, PhD, University of
Pennsylvania
11:30 – 11:50
Allopregnanolone as a Neurogenic and Cognition Enabling Therapeutic for Alzheimer's Disease: Preclinical Evidence
Roberta Brinton, PhD, University of Southern
California 11:50 am – 12:1 0
pm Panel Discussion
12:10 – 1:10 Lunch
V. IMMUNOLOGY AND ANTI-INFLAMMATION STRATEGIES
Session Chair
D. Martin Watterson, PhD,Northeastern
University
1:10 – 1:30
Immune Defects in Alzheimer’s Disease: New Medications Development
John Cashman, PhD, Human Biomolecular
Research Institute
1:30 – 1:50
Small Molecule Modulators of CNS Proinflammatory Cytokine Production
D. Martin Watterson, PhD, Northwestern
University
1:50 – 2:10 Agonists of TGFβSignaling to Treat Alzheimer's Disease Tony Wyss-Coray, PhD, Stanford University
2:10– 2:30 Panel Discussion
2:30 – 2:50 Break
VI. COGNITIVE ENHANCERS
Session Chair Antony Horton, PhD,ADDF
2:50 – 3:10
IRAP-a Novel Target for the Development of
Memory-Enhancing Agents Siew Yeen Chai, PhD, Howard Florey Institute
3:10 – 3:30
Cognitive-enhancing Effects ff Angiotensin IV: An
Investigation of Molecular Mechanisms Paul Gard, PhD, University of Brighton
3:30 – 3:50
Clinical Efficacy of AC-1202 (Ketasyn™) in Mild to Moderate Alzheimer’s Disease
Lauren C. Costantini, PhD, Accera, Inc.
(confirmed) 3:50 – 4:10 Panel Discussion
